Psoriasiform eruptions secondary to phosphoinositide 3-kinase inhibition

Abstract

The phosphoinositide 3-kinase (PI3K) pathway has key regulatory roles in cell survival, proliferation, and differentiation.1 It is among the most frequently altered pathways in human cancers, and PI3K inhibitors are used to treat a variety of malignancies.1 Class I PI3K, the best studied of the PI3K classes, is a heterodimer with both regulatory and catalytic subunits, the latter of which exists in 4 distinct isoforms (α, β, γ, and δ).2 The α and β isoforms are expressed ubiquitously, but γ and δ isoform expression is mainly found on leukocytes and cells of the adaptive immune system.